Jiuqiang Biopharmaceutical (300406.SZ) released its half-year performance, with a net profit attributable to owners of the parent company of 175 million yuan, a decrease of 30.01%.

China Fortune Finance APP News, Jiuhang Bio (300406.SZ) released its 2025 interim report, with the company's operating income at 668 million RMB, a decrease of 18.67% year-on-year. The net profit attributable to shareholders of the listed company was 175 million RMB, a decrease of 30.01% year-on-year. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 173 million RMB, a decrease of 30.08% year-on-year. The basic earnings per share were 0.3 yuan.